pyrazines has been researched along with Astrocytoma, Grade IV in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 17 (54.84) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Bindra, RS; Burgenske, DM; Dragojevic, S; Elmquist, WF; Gupta, SK; Kim, M; Mohammad, AS; Sarkaria, JN; Talele, S; Zhang, W | 1 |
| Azami Movahed, M; Bagheri, Z; Hadjighassem, M; Haghi-Aminjan, H; Pourahmad Jaktaji, R; Pourahmad, J; Rahimifard, M; Zarghi, A | 1 |
| Kapoor-Narula, U; Lenka, N | 1 |
| Ang, BT; Chong, YK; Koh, LWH; Lim, SW; Ng, WH; Sandanaraj, E; Tan, MSY; Tan, NS; Tan, P; Tang, C | 1 |
| Ang, BT; Cheng, HS; Chong, YK; Law, CLD; Low, ZYJ; Marvalim, C; Tan, NS; Tang, C; Zhu, P | 1 |
| Baird, JD; Branstrom, A; Cao, L; Colacino, JM; Dali, M; Dumble, M; Furia, B; Jernigan, F; Kim, MJ; Kong, R; Laskin, OL; Mollin, A; Moon, YC; Mühlethaler, T; O'Keefe, K; Prota, AE; Pykett, M; Sheedy, J; Sheridan, R; Spiegel, RJ; Steinmetz, MO; Weetall, M | 1 |
| Akhavan, D; Assuncao, A; Babic, I; Bonetti, B; Cavenee, WK; Chopra, R; Cloughesy, TF; Furnari, FB; Gini, B; Gu, Y; Guo, D; Heath, JR; Hege, K; Ikegami, S; James, CD; Kroemer, G; Lin, K; Masui, K; Matsutani, T; Mischel, PS; Mortensen, DS; Nathanson, D; Raymon, HK; Shackelford, D; Tanaka, K; Villa, GR; Xu, S; Yang, H; Zanca, C; Zhu, S | 1 |
| Alexandru, D; Bigner, D; Bota, DA; Friedman, HS; Keir, ST; Vredenburgh, J | 1 |
| Feng, J; Leng, X; Li, J; Li, W; Lian, S; Wang, C; Wang, H; Zhang, X | 1 |
| Gaut, D; Hu, K; Koeffler, HP; Lin, L; Yan, H; Yin, D | 1 |
| Eberhart, CG; Hayashi, M; Kahlert, UD; Koch, K; Maciaczyk, J; Natsumeda, M; Orr, BA; Suwala, AK | 1 |
| Allan, JM; Curtin, NJ; Edmondson, R; Elstob, CJ; Fordham, S; Herriott, A; May, FE; McCormick, A; Middleton, FK; Patterson, MJ; Pollard, JR; Wade, MA | 1 |
| Bonetti, B; Cavenee, WK; Chopra, R; Cloughesy, TF; Ding, X; Gini, B; Gu, Y; Heath, JR; Herrmann, K; Hwang, K; Ikegami, S; James, CD; Johnson, D; Kim, J; Li, X; Masui, K; Matsutani, T; Mischel, PS; Shin, YS; Su, Y; Wei, W; Xue, M; Yang, H; Zhou, J | 1 |
| Akkari, L; Bowman, RL; Holland, EC; Huse, JT; Joyce, JA; Quail, DF; Quick, ML; Schuhmacher, AJ; Sutton, JC | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M | 1 |
| Cadenas, E; Chen, TC; Gaffney, KJ; Golden, EB; Kardosh, A; Lam, PY; Louie, SG; Petasis, NA; Schönthal, AH | 1 |
| Barone, E; Mancuso, C | 1 |
| Brancolini, C; Florean, C; Foti, C; Gustincich, S; Pezzutto, A; Roncaglia, P; Tomasella, A | 1 |
| Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M | 1 |
| Cristofanon, S; Debatin, KM; Fulda, S; Karpel-Massler, G; Nonnenmacher, L; Unterkircher, T; Vellanki, SH; Wirtz, CR | 1 |
| Han, D; Liu, H; Liu, Y; Wang, C; Wang, Y; Wu, J; Xu, D; Yang, H; Ye, Y; Zhang, G; Zhao, S; Zhen, Y; Zheng, T | 1 |
| Blosser, W; de Maria, R; Dowless, M; Low, J; Pallini, R; Ricci-Vitiani, L; Stancato, L | 1 |
| Agostino, NR; DiDomenico, JD; Jane, EP; Pollack, IF; Premkumar, DR | 1 |
| Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C | 1 |
| Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C | 1 |
| Bruyère, C; Eamvijarn, A; Herz, W; Kijjoa, A; Kiss, R; Lefranc, F; Manoch, L; Mathieu, V; Silva, A | 1 |
| Hatzidaki, E; Koukoulis, GK; Papandreou, CN; Stathakis, NE; Vlachostergios, PJ | 1 |
| Black, KL; Koeffler, HP; Kumagai, T; Liu, G; Ong, JM; Yin, D; Zhou, H | 1 |
| Chen, J; Pamarthy, D; Sun, Y; Tan, M; Wang, S; Wu, M; Yang, D; Zhang, H | 1 |
| Chen, TC; Golden, EB; Hofman, FM; Kardosh, A; Louie, SG; Petasis, NA; Pyrko, P; Schönthal, AH; Uddin, J | 1 |
3 trial(s) available for pyrazines and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Benzimidazoles; Cell Proliferation; Female; Glioblastoma; Humans; Leiomyosarcoma; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Prognosis; Pyrazines; Tissue Distribution; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome | 2009 |
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat | 2012 |
28 other study(ies) available for pyrazines and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Brain; Cell Line, Tumor; Female; Glioblastoma; HEK293 Cells; Humans; Infusion Pumps; Isoxazoles; Male; Mice; Mice, Knockout; Mice, Nude; Pyrazines; Xenograft Model Antitumor Assays | 2021 |
Assessment of cytotoxic effects of new derivatives of pyrazino[1,2-a] benzimidazole on isolated human glioblastoma cells and mitochondria.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzimidazoles; Biomarkers, Tumor; Brain Neoplasms; Caspase 3; Cell Survival; Glioblastoma; HEK293 Cells; Humans; Mitochondria; Pyrazines; Spectrum Analysis; Tumor Cells, Cultured | 2021 |
Elucidating the Anti-Tumorigenic Efficacy of Oltipraz, a Dithiolethione, in Glioblastoma.
Topics: Animals; beta Catenin; Carcinogenesis; Caspase 3; Cell Line, Tumor; Glioblastoma; Glutathione; HEK293 Cells; Humans; Mice; Mice, SCID; Neoplastic Stem Cells; Nestin; Pyrazines; Reactive Oxygen Species; Thiones; Thiophenes; Vimentin | 2022 |
A STAT3-based gene signature stratifies glioma patients for targeted therapy.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Predisposition to Disease; Glioblastoma; Humans; Imidazoles; Insulin-Like Growth Factor Binding Protein 2; Mice; Pyrazines; Pyrazoles; Pyrimidines; Receptor, IGF Type 1; STAT3 Transcription Factor; Temozolomide; Xenograft Model Antitumor Assays | 2019 |
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation.
Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Hypoxia; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrrolidinones; Quinolines; Signal Transduction; Temozolomide; Transcriptome; Triazoles | 2021 |
The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Glioblastoma; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Protein Biosynthesis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Glioblastoma; Glioma; Humans; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Temozolomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells.
Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Mitochondria; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Signal Transduction; Ubiquitin-Activating Enzymes | 2014 |
Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Proliferation; Drug Synergism; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Triazines; Tumor Cells, Cultured | 2014 |
Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells.
Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Glioblastoma; Humans; Pyrazines; Pyridines; Tumor Stem Cell Assay; Wnt Signaling Pathway | 2015 |
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; CHO Cells; Computational Biology; Cricetinae; Cricetulus; Databases, Genetic; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Molecular Targeted Therapy; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Sulfones; Time Factors; Transfection | 2015 |
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.
Topics: Adaptation, Physiological; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Profiling; Genes, erbB-1; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Models, Biological; Molecular Targeted Therapy; Multiprotein Complexes; Mutation; Neoplasm Proteins; Nitriles; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Pyrazines; Selection, Genetic; Signal Transduction; Single-Cell Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Drug Resistance, Neoplasm; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Insulin-Like Growth Factor I; Macrophages; Mice; Mice, Inbred Strains; Neoplasm Recurrence, Local; Neoplasms, Experimental; NFATC Transcription Factors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Picolinic Acids; Pyrazines; Receptor, IGF Type 1; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; STAT6 Transcription Factor; Tumor Microenvironment | 2016 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Color; Cytoprotection; Endoplasmic Reticulum; Enzyme Inhibitors; Flavonoids; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Structure; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tea | 2009 |
Therapeutic use of tea derivatives: all that glitters is not gold.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Color; Cytoprotection; Endoplasmic Reticulum; Enzyme Inhibitors; Flavonoids; Glioblastoma; Humans; Mice; Mice, Nude; Molecular Structure; Phenols; Plant Extracts; Polyphenols; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Tea | 2009 |
Characterization of caspase-dependent and caspase-independent deaths in glioblastoma cells treated with inhibitors of the ubiquitin-proteasome system.
Topics: Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Gene Expression Profiling; Glioblastoma; Glutathione; Humans; Microarray Analysis; Necrosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrans; Pyrazines; Sulfhydryl Compounds; Ubiquitin | 2009 |
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured | 2009 |
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Death Domain Receptor Signaling Adaptor Proteins; Glioblastoma; Humans; Mitochondria; Neoplastic Stem Cells; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2011 |
Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.
Topics: Antineoplastic Agents; Apoptosis; Benzhydryl Compounds; Boronic Acids; Bortezomib; Brain; Cell Line, Tumor; Cell Nucleus; DNA-Binding Proteins; Gene Knockdown Techniques; Glioblastoma; Heat Shock Transcription Factors; Hot Temperature; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; JNK Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Pyrrolidinones; RNA, Small Interfering; Transcription Factors; Up-Regulation | 2012 |
Knockdown of ubiquitin ligases in glioblastoma cancer stem cells leads to cell death and differentiation.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Humans; Neoplastic Stem Cells; Nocodazole; Pyrazines; RNA Interference; RNA, Small Interfering; Signal Transduction; Ubiquitin-Protein Ligases | 2012 |
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Central Nervous System Neoplasms; Cytochromes c; DNA Damage; Glioblastoma; Glioma; Histones; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Membrane Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Tumor Cells, Cultured; Vorinostat | 2013 |
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Neural Stem Cells; Phenylbutyrates; Pyrazines; Valproic Acid; Vorinostat | 2012 |
Secondary metabolites from a culture of the fungus Neosartorya pseudofischeri and their in vitro cytostatic activity in human cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cytostatic Agents; Dioxoles; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; MCF-7 Cells; Microscopy, Phase-Contrast; Mitosis; Neosartorya; Pyrazines; Pyridines; Sesquiterpenes; Soil Microbiology | 2012 |
Bortezomib downregulates MGMT expression in T98G glioblastoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; NF-kappa B; Pyrazines; Signal Transduction; Tumor Suppressor Proteins | 2013 |
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Glioblastoma; Humans; Models, Biological; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.
Topics: Animals; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Ellipticines; Glioblastoma; Humans; Leupeptins; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; S-Phase Kinase-Associated Proteins; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases | 2007 |
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Celecoxib; Cell Death; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Glioblastoma; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Pyrazines; Pyrazoles; Sulfonamides; Transfection; Xenograft Model Antitumor Assays | 2008 |